GeneNews' Q2 Loss Rises on Higher R&D Costs | GenomeWeb
NEW YORK (GenomeWeb News) – GeneNews today reported that its net loss rose 74 percent year over year on higher R&D costs as the firm rolled its first commercial biomarker test.
 
The Toronto-based firm brought in revenues of $288,438 for the three-month period ended June 30, compared to no revenues in the second quarter of 2007. It said revenue from the most recent quarter came from a collaboration with an Asian biomedical consortium to identify and validate a set of biomarkers for prostate disease.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.